Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. 1995

L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
Department of Ophthalmology, Shiley Eye Center, University of California at San Diego, La Jolla 92093-0946, USA.

OBJECTIVE The authors previously conducted a pilot, dose-escalating study which suggested that a 20-micrograms dose of intravitreal cidofovir (HPMPC) may be safe and effective in treating cytomegalovirus (CMV) retinitis in humans. The purpose of this series is to expand the authors' prior experience with the 20-micrograms dose of cidofovir as the sole treatment for CMV retinitis in patients with acquired immune deficiency syndrome. METHODS The study design was an unmasked consecutive case series trial in a single-center institutional retina referral practice. Eligible patients with acquired immune deficiency syndrome had active CMV retinitis in at least one eye and no evidence of extraocular CMV disease. Patients received a 20-micrograms cidofovir trans pars plana injection and were treated with concomitant oral probenecid. Retreatments were performed for progression of retinitis as determined by serial fundus photographs judged independently by three observers. The primary outcome was time to retinitis progression determined by Kaplan-Meier analysis. Both globes of one patient who had unilateral retinitis were examined pathologically. RESULTS There were 37 cidofovir injections in 24 eyes of 17 patients. The median time to retinitis progression after the initial 24 injections was 55 days. The median time to retinitis progression after 8 repeat cidofovir injections was 63 days. There was a significant decrease in intraocular pressure from baseline to both 2 and 4 weeks after injection. A mild to moderate iritis developed in five (20.8%) eyes that responded well to topical medications. Results of histopathologic examination of one treated globe did not show any significant toxic effects. CONCLUSIONS This study demonstrates that prolonged arrest of the progression of CMV retinitis may be obtained with a single 20-micrograms cidofovir intravitreal injection. In addition, the effect of the drug appears to be maintained after a second injection. The effects of cidofovir in causing uveitis and a slight lowering of the intraocular pressure require further study.

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D007429 Intraocular Pressure The pressure of the fluids in the eye. Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D002924 Ciliary Body A ring of tissue extending from the scleral spur to the ora serrata of the RETINA. It consists of the uveal portion and the epithelial portion. The ciliary muscle is in the uveal portion and the ciliary processes are in the epithelial portion. Corpus Ciliare,Corpus Ciliaris,Bodies, Ciliary,Body, Ciliary,Ciliare, Corpus,Ciliares, Corpus,Ciliari, Corpus,Ciliaris, Corpus,Ciliary Bodies,Corpus Ciliares,Corpus Ciliari
D003596 Cytosine A pyrimidine base that is a fundamental unit of nucleic acids.
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
June 1997, Ophthalmology,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
October 1999, Postgraduate medical journal,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
August 1997, American journal of ophthalmology,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
September 1991, Ophthalmology,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
September 1998, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
November 1997, Ophthalmology,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
July 1996, Ophthalmology,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
June 1989, Ophthalmology,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
November 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
L S Kirsch, and J F Arevalo, and E Chavez de la Paz, and D Munguia, and E de Clercq, and W R Freeman
January 2000, European journal of ophthalmology,
Copied contents to your clipboard!